References
- 1. Abdelnabi R., Neyts J. i wsp.: A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol. 17, e3000281 (2019)
- 2. Abzug M.J.: Presentation, diagnosis, and management of enterovirus infections in neonates. Paediatr. Drugs. 6, 1–10 (2004)
- 3. Agrez M.V., Shafren D.R., Gu X., Cox K., Sheppard D., Barry R.D.: Integrin avb6 enhances coxsackievirus B1 lytic infection of human colon cancer cells. Virology, 239, 71–77 (1997)
- 4. Albulescu L., Strating J.R.P.M., Thibaut H.J., van der Linden L., Shair M.D., Neyts J., van Kuppeveld F.J.M.: Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. Antivir. Res. 117, 110–114 (2015)
- 5. Angez M., Shaukat S., Zahra R., Alam M., Sharif S., Khurshid A., Zaidi S.: Characterization of group B coxsackieviruses isolated from non-polio acute flaccid paralysis patients in Pakistan: Vital Assessment Before polio eradication. Epidemiol. Infecti. 145, 2473–2481 (2017)
- 6. Argo E., Gimenez B., Cash P.: Non-cytopathic infection of rhabdomyosarcoma cells by coxsackie B5 virus. Arch.Virol. 126, 215–229 (1992)
- 7. Baboonian C., Davies M.J., Booth J.C., McKenna W.J.: Coxsackie B viruses and human heart disease. Curr. Top. Microbiol. Immunol. 223, 31–52 (1997)
- 8. Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M.: The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368–381 (2018)
- 9. Basavappa R., Filman D.J., Syed R., Flore O., Icenogle J.P., Hogle J.M.: Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: Structure of the empty capsid assembly intermediate at 2.9 Å resolution. Protein Sci. 3, 1651–1669 (1994)
- 10. Bedard K.M., Semler B.L.: Regulation of picornavirus gene expression. Microbes. Infect. 6, 702–713 (2004)
- 11. Bergelson J.M., Modlin J.F., Wieland-Alter W., Cunningham J.A., Crowell R.L., Finberg R.W.: Clinical Coxsackievirus B Isolates Differ from Laboratory Strains in Their Interaction with Two Cell Surface Receptors. J. Infect Dis. 175, 697–700 (1997)
- 12. Bersani I., Auriti C., Piersigilli F., Dotta A., Diomedi-Camassei F., Di Pede A., Buttinelli G., Danhaive O.: Neonatal Acute Liver Failure Due to enteroviruses: a 14 years single NICU experience. J. Matern. Fetal. Neonatal. Med. 33, 2576–2580 (2020)
- 13. Billaud G., Peny S., Legay V., Lina B., Valette M.: Detection of rhinovirus and enterovirus in upper respiratory tract samples using a multiplex nested PCR. J. Virol. Methods. 108, 223–228 (2003)
- 14. Bissel S.J., Winkler C.C., DelTondo J., Wang G., Williams K., Wiley C.A.: Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathology, 34, 429–437 (2014)
- 15. Bopegamage S.: Enterovirus infections: Pivoting role of the adaptive immune response. Virulence, 7, 495–497 (2016)
- 16. Buchwald D., Ashley R.L., Pearlman T., Kith P., Komaroff A.L.: Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. J. Med. Virol. 50, 25–30 (1996)
- 17. Chrysos G., Kokkoris S., Protopsaltis J., Korantzopoulos P., Giannoulis G.: Coxsackievirus infection associated with acute pancreatitis. JOP, 5, 384–387 (2004)
- 18. Chu P.Y., Motomura K. i wsp.: Transmission and Demographic Dynamics of Coxsackievirus B1. PLoS One, 10, e0129272 (2015)
- 19. Chung S.K., Kim J.Y., Kim I.B., Park S. I, Paek K.H, Nam J.H: Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells. Virology, 333, 31–40 (2005)
- 20. Coyne C.B., Shen L., Turner J.R., Bergelson J.M.: Coxsackievirus Entry across Epithelial Tight Junctions Requires Occludin and the Small GTPases Rab34 and Rab5. Cell Host. Microbe. 2, 181–192 (2007)
- 21. Crowell R.L., Landau B.J.: A short history and introductory background on the coxsackieviruses of group B. Curr. Top. Microbiol. Immunol. 223, 1–11 (1997)
- 22. Dalldorf G., Sickles G.M., Plager H., Gifford, R.: A virus recovered from the feces of poliomyelitis patients pathogenic for suckling mice. J. Exp. Med. 89, 567–582 (1949)
- 23. Dan M., Chantler J.K.: A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal injection. J. Virol. 79, 9285–9295 (2005)
- 24. Domingo E., Martin V., Perales C., Escarmis C.: Coxsackieviruses and Quasispecies Theory: Evolution of Enteroviruses (w) Group B Coxsackieviruses, red. Tracy S., Oberste M.S., Drescher K.M. Curr Top in Microbiol. Immunol. 323, 3–32 (2008)
- 25. Druyts-Voets E., Van Renterghem L., Gerniers S.: Coxsackie B virus epidemiology and neonatal infection in Belgium. J. Infect. 27, 311–316 (1993)
- 26. Dutkiewicz M., Stachowiak A., Swiatkowska A., Ciesiołka J.: Structure and function of RNA elements present in enteroviral genomes. Acta. Biochim. Pol. 63, 623–630 (2016)
- 27. Duyvesteyn H.M.E., Ren J., Walter T.S., Fry E.E., Stuart D.I.: Glutathione facilitates enterovirus assembly by binding at a druggable pocket. Commun. Biol. 3, DOI: 10.1038/s42003-019-0722-x. (2020)
- 28. Euscher E., Davis J., Holzman I., Nuovo G.J: Coxsackie virus infection of the placenta associated with neurodevelopmental delays in the newborn. Obstet. Gynecol. 98, 1019–1026 (2001)
- 29. Frisk G., Lindberg M.A., Diderholm H.: Persistence of coxsackievirus B4 infection in rhabdomyosarcoma cells for 30 months. Brief report. Arch. Virol. 144, 2239–2245 (1999)
- 30. Garmaroudi F.S., Marchant D., Hendry R., Luo H., Yang D., Ye X., Shi J., McManus B.M.: Coxsackievirus B3 replication and pathogenesis. Future Microbiol. 10, 629–653 (2015)
- 31. Gazina E.V., Smidansky E.D., Holien J.K., Harrison D.N., Cromer B.A., Arnold J.J., Parker M.W., Cameron C.E., Petrou S.: Amiloride is a competitive inhibitor of coxsackievirus B3 RNA polymerase. J. Virol. 85, 10364–10374 (2011)
- 32. Ghigo E.: A dilemma for viruses and giant viruses: which endocytic pathway to use to enter cells? Intervirology, 53, 274–283 (2010)
- 33. Gofshteyn J., Cárdenas A.M., Bearden D.: Treatment of Chronic Enterovirus Encephalitis With Fluoxetine in a Patient With X-Linked Agammaglobulinemia. Pediatr. Neurol. 64, 94–98 (2016)
- 34. Harvala H., Fischer T.K. i wsp.: Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J. Clin. Virol. 101, 11–17 (2018)
- 35. Hopkins K.A., Abdou M.H., Hadi M.A.: Coxsackie B2 Virus Infection Causing Multiorgan Failure and Cardiogenic Shock in a 42-Year-Old Man. Tex. Heart. Inst. J. 46, 32–35 (2019)
- 36. Hunziker I.P., Harkins S., Feuer R., Cornell C.T., Whitton J.L.: Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology, 330, 196–208 (2004)
- 37. Hyöty H., Leon F., Knip M.: Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert. Rev. Vaccines. 17, 1071–1080 (2018)
- 38. Ifie E., Richardson S.J. i wsp.: Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia, 61, 2344–2355 (2018)
- 39. Iturriza-Gómara M., Megson B., Gray J.: Molecular detection and characterization of human enteroviruses directly from clinical samples using RT-PCR and DNA sequencing. J. Med. Virol. 78, 243–253 (2006)
- 40. Kang H., Cho, S. i wsp.: Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral. Res. 124, 1–10 (2015)
- 41. Kaplan M.H., Klein S.W., McPhee J., Harper R.G.: Group B Coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev. Infect. Dis. 5, 1019–1032 (1983)
- 42. Khetsuriani N., Lamonte-Fowlkes A., Oberst S., Pallansch M.A.: Enterovirus surveillance – United States, 1970–2005. MMWR Surveill. Summ. 55, 1–20 (2006)
- 43. Knowlton K.U.: CVB infection and mechanisms of viral cardiomyopathy. Curr. Top. Microbiol. Immunol. 323, 315–335 (2008)
- 44. Krogstad P., Hammon R., Halnon N., Whitton J.L.: Fatal neonatal myocarditis caused by a recombinant human enterovirus-B variant. Pediatr. Infect. Dis. J. 27, 668–669 (2008)
- 45. Kyriakopoulou Z., Pliaka V., Amoutzias G.D., Markoulatos P.: Recombination among human non-polio enteroviruses: implications for epidemiology and evolution. Virus. Genes. 50, 177–188 (2015)
- 46. Lee S.H.: Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest. Res. 13, 11–18 (2015)
- 47. Lin J.-Y., Chen T.-C., Weng K.-F., Chang S.-C., Chen L.-L., Shih S.-R.: Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci. 16, 103 (2009)
- 48. Linden L., Wolthers K., van Kuppeveld F.: Replication and Inhibitors of Enteroviruses and Parechoviruses. Viruses, 7, 4529–4562 (2015)
- 49. Ma H., Huang X., Kang K., Li X., Tang X., Ren Y., Wang Y., Zhao G., Xu B.: Recombination in human coxsackievirus B5 strains that caused an outbreak of viral encephalitis in Henan, China. Arch. Virol. 158, 2169–2173 (2013)
- 50. Martínez-Salas E., Francisco-Velilla R., Fernandez-Chamorro J., Lozano G., Diaz-Toledano R.: Picornavirus IRES elements: RNA structure and host protein interactions. Virus. Res. 206, 62–73 (2015)
- 51. Melchers W.J., Hoenderop J.G., Bruins Slot H.J., Pleij C.W., Pilipenko E.V., Agol V.I., Galama J.M.: Kissing of the two predominant hairpin loops in the coxsackie B virus 3’ untranslated region is the essential structural feature of the origin of replication required for negative-strand RNA synthesis. J. Virol. 71, 686–696 (1997)
- 52. Mercer J., Helenius A.: Virus entry by macropinocytosis. Nat. Cell Biol. 11, 510–520 (2009)
- 53. Muehlenbachs A., Bhatnagar J., Zaki, S.R.: Tissue tropism, pathology and pathogenesis of enterovirus infection. J. Pathol. 235, 217–228 (2014)
- 54. Muslin C., Kain A.M., Bessaud M., Blondel B., Delpeyroux F.: Recombination in Enteroviruses, a Multi-Step Modular Evolutionary Process. Viruses, 11, 859 (2019)
- 55. Oikarinen M., Hyöty H. i wsp.: Analysis of pancreas tissue in a child positive for islet cell antibodies. Diabetologia, 51, 1796–1802 (2008)
- 56. Oikarinen S., Hyöty H. i wsp.: Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 63, 655–662 (2016)
- 57. Ornoy A., Tenenbaum A.: Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod. Toxicol. 21, 446–457 (2006)
- 58. Panwar H.S., Ojha H., Ghosh P., Barage S.H., Raut S., Sahu A.: Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins. Proc. Natl. Acad. Sci. USA, 116, 9953–9958 (2019)
- 59. Peischard S., Ho H.T., Theiss C., Strutz-Seebohm N., Seebohm G.: A Kidnapping Story: How Coxsackievirus B3 and Its Host Cell Interact. Cell Physiol. Biochem. 53, 121–140 (2019)
- 60. Pérez-Losada M., Arenas M., Galán J. C., Palero F., González-Candelas F.: Recombination in viruses: mechanisms, methods of study, and evolutionary consequences. Infect. Genet. Evol. 30, 296–307 (2015)
- 61. Pinkert S., Dieringer B., Diedrich S., Zeichhardt H., Kurreck J., Fechner H.: Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus. Antiviral. Res. 136, 1–8 (2016)
- 62. Pinkert S., Röger C., Kurreck J., Bergelson J. M., Fechner H.: The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection. J. Virol. 90, 5601–5610 (2016)
- 63. Rotbart H.A.: Enteroviral infections of the central nervous system. Clin. Infect. Dis. 20, 971–981 (1995)
- 64. Schmidtke M., Selinka H. C., Heim A., Jahna B., Tonewa M., Kandolfb R., Stelznera A., Zella R.: Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1. Virology, 275, 77–88 (2000)
- 65. Schultz J.C., Hilliard A.A., Cooper L.T., Rihal C.S.: Diagnosis and treatment of viral myocarditis. Mayo. Clin. Proc. 84, 1001–1009 (2009)
- 66. Shen H.: Recombination analysis of coxsackievirus B5 genogroup C. Arch. Virol. 163, 539–544 (2018)
- 67. Sin J., Mangale V., Thienphrapa W., Gottlieb R. A., Feuer R.: Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology, 484, 288–304 (2015)
- 68. Smith A.D., Dawson H.: Glutathione is required for efficient production of infectious picornavirus virions. Virology, 353, 258–267 (2006)
- 69. Sun D., Chen X. i wsp.: Apoptosis and Autophagy in Picornavirus Infection. Front. Microbiol. 10,
- 70. Tang J.W., Holmes C.W.: Acute and chronic disease caused by enteroviruses. Virulence, 8, 1062–1065 (2017)
- 71. Thanaviratananich S, Katirji B.: Myasthenia Gravis following Coxsackie Encephalitis. SAJ Case Rep. 4, 304 (2017)
- 72. Thevenin T., Lobert P.E., Hober D.: Inactivation of coxsackievirus B4, feline calicivirus and herpes simplex virus type 1: unexpected virucidal effect of a disinfectant on a non-enveloped virus applied onto a surface. Intervirology, 56, 224–230 (2013)
- 73. Thibaut H.J., Neyts J. i wsp.: Binding of glutathione to enterovirus capsids is essential for virion morphogenesis. PLoS Pathog. 10, e1004039 (2014)
- 74. Triantafyllopoulou A., Tapinos N., Moutsopoulos H.M.: Evidence for coxsackievirus infection in primary Sjögren’s syndrome. Arthritis. Rheum. 50, 2897–2902 (2004)
- 75. Tsuno K., Miyatake C., Nishijima H., Hotta C., Ogawa T., Asano T.: Coxsackievirus B5 Aseptic Meningitis in Infants in Chiba Prefecture, Japan, in 2016. J. Nippon. Med. Sch. 85, 187–190 (2018)
- 76. Ulferts R., de Boer S.M., van Kuppeveld F.J.M. i wsp.: Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob. Agents and Chemother. 60, 2627–2638 (2016)
- 77. Van der Schaar H.M., van Kuppeveld F.J.M. i wsp.: Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res. 22, 1576–1592 (2012)
- 78. Volle R., Nourrisson C., Mirand A., Regagnon C., Chambon M., Henquell C., Bailly J.-L., Peigue-Lafeuille H., Archimbaud C.: Quantitative real-time RT-PCR assay for research studies on enterovirus infections in the central nervous system. J. Virol. Methods. 185, 142–148 (2012)
- 79. Volobueva A., Egorova A., Galochkina A., Ekins S., Zarubaev V., Makarov V.: The Evolution of Pleconaril: Modified O-Alkyl Linker Analogs Have Biological Activity towards Coxsackievirus B3 Nancy. Molecules, 25,
- 80. Vonlaufen A., Wilson J.S., Apte M.V.: Molecular mechanisms of pancreatitis: current opinion. J. Gastroenterol. Hepatol. 23, 1339–1348 (2008)
- 81. Wehbi A., Kremer E.J., Dopeso-Reyes I.G.: Location of the Cell Adhesion Molecule “Coxsackievirus and Adenovirus Receptor” in the Adult Mouse Brain. Front. Neuroanat. 14, DOI: 10.3389/fnana.2020.00028 (2020)
- 82. Xiang W., Paul A.V., Wimmer E.: RNA Signals in Entero- and Rhinovirus Genome Replication. Seminars in Virology, 8, 256–273 (1997)
- 83. Zaragoza C., Ocampo C., Saura M., Leppo M., Wei X.-Q., Quick R., Moncada S., Liew F.Y., Lowenstein, C.J.: The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc. Natl. Acad. Sci. USA, 95, 2469–2474 (1998)
- 84. Zautner A.E., Korner U., Henke A., Badorff C., Schmidtke M.: Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J. Virol. 77, 10071–10077 (2003)
- 85. Zell R. and ICTV Report Consortium: ICTV VirusTaxonomy Profile. Picornaviridae. J. Gen. Virol. 98, 2421–2422 (2017)